FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer
February 14, 2018 – Today the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, also previously called ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). This...Read More
Two new treatments have been found for prostate cancer patients who previously had no effective treatment options
Over the course of prostate cancer progression, there can come a time during which the cancer is progressing, but there are no treatments known to improve survival. One of these...Read More
FDA approves Abiraterone + Prednisone for Earlier Treatment of Metastatic Prostate Cancer
Back in June, we told you about the early results of the LATITUDE clinical trial, presented at the 2017 ASCO conference. The study indicated that giving abiraterone in combination with...Read More
2017 ASCO Meeting: Results from the LATITUDE Study
If you have just been diagnosed with metastatic prostate cancer and your doctor wants to start you on ADT (androgen deprivation therapy, such as Lupron), which shuts off the supply...Read More
- 1
- 2